- Home
- FRBA vs CLLS Comparison
FRBA vs CLLS Comparison
Compare FRBA & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRBA | CLLS |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | France |
| Employees | 336 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.6M | 394.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | FRBA | CLLS |
|---|---|---|
| Price | $18.62 | $2.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $17.50 | $8.33 |
| AVG Volume (30 Days) | ★ 90.1K | 15.2K |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.68 | N/A |
| Revenue Next Year | $6.08 | $0.98 |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.41 | $2.35 |
| 52 Week High | $19.09 | $5.48 |
Technical Indicators
Market Signals| Indicator | FRBA | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 64.25 | 39.48 |
| Support Level | $16.84 | $2.65 |
| Resistance Level | $19.09 | $2.98 |
| Average True Range (ATR) | 0.57 | 0.15 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 87.18 | 53.13 |
Price Performance
Historical ComparisonAbout FRBA First Bank
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of business. Its services are Business Banking, Personal Banking, Digital Banking, and Lending.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.